A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
Phase 2
Completed
NCT05258071
| Condition | Parkinson Disease |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Integrative Research Laboratories AB |
|---|
| Status | Completed |
|---|
| Enrollment | 104 participants |
|---|
| Interventions | Pirepemat |
|---|
| Start date | Jun 15, 2022 |
|---|
| Completion date | Dec 4, 2024 |
|---|
| Results posted | Jul 9, 2026 |
|---|
Summary
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.
Baseline to end of full dose treatment (up to Day 84). · % of baseline fall rate
| Pirepemat 300 mg | 76.9 ± 72.05 % of baseline fall rate |
|---|
| Pirepemat 600 mg | 64.5 ± 49.18 % of baseline fall rate |
|---|
| Placebo | 68.9 ± 90.22 % of baseline fall rate |
|---|
| p-value | 0.5753 |
|---|
| Median ratio | 0.973 (95% CI 0.706–1.274) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.